Trial Profile
A PROSPECTIVE, MULTICENTER, PHASE-II TRIAL EVALUATING EFFICACY AND SAFETY OF BENDAMUSTINE + GA101 (BG) IN PATIENTS WITH RELAPSED CLL FOLLOWED BY MAINTENANCE THERAPY WITH GA101 FOR RESPONDING PATIENTS.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamides; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2016 Number of treatment arms changed from 2 to 1. Study design was changed from randomized to non-randomized, parallel to single-group assessment.
- 05 Oct 2016 Planned number of patients changed from 100 to 60.